Global Medical Device Nomenclature (GMDN) Agency has launched its new five-year strategy for 2022-2026 that sets out its vision for growth and increased global harmonisation.
John Wilkinson, chair of trustees, sets out what the new strategy aims to achieve: “Our new strategy marks a significant shift from just providing a well-constructed and maintained set of definitions to supporting the development and use of the nomenclature in a wide variety of applications. We are investing more of our time and efforts into helping with application development, exploring new uses with our community, and ensuring that users can get the best from this unique resource.”
The strategy sets out five specific programmes of work that will drive its development in the coming years. These are:
- New legacy transition tools: To support users to transition away from their legacy nomenclature, by providing a service to help convert their existing data to use GMDN Terms
- A Bespoke device grouping service: This will allow users to make their own groups of GMDN Terms for a specific purpose.
- Term Assignment Support programme: Implementing a plan of surveillance to identify errors in GMDN / product assignment and feed this information back to members.
- Stakeholder Outreach: Initiating a programme which identifies stakeholder groups that can help contribute to the development, utility, and efficacy of GMDN.
- Harmonisation support: Creating resources to support international cooperation - this programme could include sharing real-world evidence of device efficacy, to support the evaluation of new technology and monitor long-term device safety.
Read the GMDN Strategy 2022 - 2026 in full: https://buff.ly/3KQSwuI
Mark Wasmuth, chief executive of GMDN, says: “We look forward to a new decade of exploring the use of GMDN with our members, because we believe we are part of something bigger than just us and better identification of devices is something we all aspire to. As we all know, better data makes better decisions.”